Conference Track

Treatment of HCV

Source: CCO Independent Conference Coverage of the 2004 Annual Meeting of The American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

16 Weeks of Peginterferon Plus Ribavirin as Effective as 24 Weeks for HCV Genotype 2 and 3 in Pilot Study
NM283, an Experimental Polymerase Inhibitor, Demonstrates Efficacy for HCV Genotype 1
Weight-Based Ribavirin Dosing Improved SVR for Blacks Infected With HCV Genotype 1
Extended Treatment With Peginterferon Plus Ribavirin Reduces Relapse Rates, but With Higher Discontinuation Rate
Low-Dose Peginterferon Prevents Complications of Cirrhosis Better Than Colchicine in Interim Analysis
Comparison of Black and Nonblack Nonresponders Treated With Interferon alfacon-1 Plus Ribavirin
Prolonged Therapy With Peginterferon Plus Ribavirin May Improve SVR in Slow-Responding Patients With HCV Genotype 1 Infection
Short-Course Peginterferon Plus Ribavirin Effective for Patients With HCV Genotype 2/3 Achieving Early Response
Retreatment With Daily Consensus Interferon plus Ribavirin Appears Safe and Effective in Prior Nonresponders to Standard Interferon and Ribavirin for Chronic HCV
Antiviral Therapy Reduces Portal Vein Pressure in Patients With Chronic HCV and Moderate-to-Severe Fibrosis
HCV Genotype 2 and 3 Have Similar SVR to Peginterferon Alfa-2a Plus Ribavirin, Regardless of Length of Treatment, Ribavirin Dose, or Baseline Viral Load
Three-Month Course of Peginterferon Effective for Acute Hepatitis C
Peginterferon Monotherapy Superior to Standard Interferon Plus Ribavirin for Acute HCV Genotype 1/4
Hyperinsulinemia Appears to Diminish the Antiviral Capacity of Interferon
Donor HLA Genotype Influences the Recipient CD8+ T-cell Population After Liver Transplantation
Daily Cannabis Use Increases Risk of Fibrosis Progression in Chronic Hepatitis C

Expert Analysis

Treatment of HCV

Program Director: Patrick J. Lynch, MD

Faculty:

Gary L. Davis, MD
Adrian M. Di Bisceglie, MD, FACP
Karen L. Lindsay, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe new insights into factors complicating successful treatment, including genotype and ethnic group
Review the results of recent studies evaluating the use of FDA-approved agents, including peginterferon/ribavirin, in first-line treatment of HCV infection, as well as length of treatment with these agents
Evaluate the results of trials of drugs in development for treatment of HCV infection

Earn CME credit by reading the expert analysis and commentary on Treatment of HCV.

Topics covered include:

Extended Treatment for HCV Genotype 1
Shorter Treatment for HCV Genotypes 2 and 3
Consensus Interferon for Treatment Nonresponders
Maintenance Interferon for Preventing Disease Progression
Treatment of Acute Hepatitis C
Insulin Resistance and Liver Disease
New Drugs: Viramidine, NM283, and Others
'Reefer' Fibrosis

CME CREDIT INFORMATION

Release Date: 12/09/04

Expiration Date: 12/08/05

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Registered Nurses: 3.0 Nursing CE credits

Pharmacists: 2.5 contact hours (0.25 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.